<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381326</url>
  </required_header>
  <id_info>
    <org_study_id>IRSTB030</org_study_id>
    <nct_id>NCT03381326</nct_id>
  </id_info>
  <brief_title>CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.</brief_title>
  <acronym>IRSTB030</acronym>
  <official_title>Biomarkers Study: Circulating Tumor Cells (CTC), Free DNA, Stem Cells and Epithelial-mesenchymal-transition (EMT) Related Antigens as Biomarkers of Activity of Cabazitaxel in Castration-resistant Prostate Cancer (CRPC): a Proof of Concept.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identification of biomarkers (Circulating Tumor Cells (CTC), free DNA, Stem Cells and&#xD;
      EMT-related antigens) that may be predictive of outcome of activity of cabazitaxel treatment&#xD;
      in castration-resistant prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Circulating Tumor Cells, free DNA, Stem Cells and EMT-related antigens as biomarkers of&#xD;
      activity of cabazitaxel in castration-resistant prostate cancer&#xD;
&#xD;
      Primary objectives: To evaluate the prognostic role of response of the copy number of&#xD;
      androgen receptor (AR) and Phosphatase and tensin homolog (PTEN) and AR-V7 and other gene&#xD;
      expression biomarkers in CTC and the investigators will compare these results with those&#xD;
      obtained in plasma cell free DNA and RNA.&#xD;
&#xD;
      Eligible patients must have histologically or cytologically confirmed prostate cancer or&#xD;
      unequivocal increased PSA . Metastatic and/or inoperable disease and received prior therapy&#xD;
      with docetaxel and candidate to cabazitaxel treatment.&#xD;
&#xD;
      All patients receive cabazitaxel at standard schedule 25 mg/m2 q21. Blood sample will be&#xD;
      collected for CTC evaluation at baseline, after the first cycle of therapy (optional), at&#xD;
      first radiological evaluation (after 3 months), at disease progression (optional) or after&#xD;
      9-12 months of treatment for patients who did not show disease progression (optional).&#xD;
      Disease progression defined according to Prostate Cancer Working Group 2 (PCWG2) criteria. On&#xD;
      blood samples from Castration-Resistant Prostate Cancer (CRPC) patients the investigators&#xD;
      will investigate the presence of the previously presented CTC, DNA and RNA free markers.&#xD;
&#xD;
      As an option, it will be possible to require a sample of the tumor collected during prostate&#xD;
      surgery or during the biopsy.&#xD;
&#xD;
      All patients will be treated and monitored according to the local clinical practice. No&#xD;
      additional procedures/patient visits in comparison with the usual clinical practice are&#xD;
      planned for the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 15, 2014</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>time between the start of cabazitaxel and the ﬁrst date of progression as measured by PCWG-2 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>The overall survival will be calculated from date of the start of cabazitaxel to death</description>
  </secondary_outcome>
  <enrollment type="Actual">94</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Castration-resistant Prostate Cancer</condition>
  <condition>Circulating Tumor Cells</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood and FFPE sample collection</intervention_name>
    <description>blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples and FFPE samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with castration-resistant prostate cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          2. Male aged &gt;18 years with metastatic castration-resistant disease with documented&#xD;
             clinical (imaging) and/or biochemical progression (PSA increasing values) during or&#xD;
             after a previous docetaxel-based chemotherapy&#xD;
&#xD;
          3. Patients must have metastatic and/or inoperable disease&#xD;
&#xD;
          4. Patients must have received prior therapy docetaxel based and must be candidate to&#xD;
             cabazitaxel&#xD;
&#xD;
          5. Life expectancy of greater than 3 months&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status &lt;2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants who are unable to provide informed consent&#xD;
&#xD;
          2. Participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ugo De Giorgi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedali Riuniti Umberto I</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS AOU San martino IST</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile degli Infermi</name>
      <address>
        <city>Rimini</city>
        <state>RN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Cannizzaro</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico del Veneto (IOV) - Università di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore Don Calabria (Negrar)</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>circulating tumor cells</keyword>
  <keyword>Castration-resistant Prostate Cancer</keyword>
  <keyword>cabazitaxel</keyword>
  <keyword>biomarker</keyword>
  <keyword>free DNA</keyword>
  <keyword>stem cells</keyword>
  <keyword>EMT related antigens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

